# Prelude Therapeutics Incorporated (PRLD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.46, market value $436 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Prelude Therapeutics Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 35.9×**. Each dollar of revenue is priced at 35.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.2×**. The shares trade at 4.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -7.6%** (5-yr avg -44.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -861.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -819.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -145.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -70.4%**. Each dollar of assets produces -70.4% of profit.

## Growth
- **Revenue growth (1 yr): 73.4%**. Revenue grew 73.4% over the last year.
- **EPS growth (1 yr): 23.2%**. Earnings per share rose 23.2%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 1.99** (quick 1.99). Current assets cover the next year's liabilities 1.99 times.
- **Altman Z-score: 2.37**. A Z-score of 2.37 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Prelude Therapeutics Incorporated does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 378.9%** (YTD 88.3%, 3-mo 43.3%). The shares are up 378.9% over twelve months including dividends.
- **From 52-week high: -20.1%** (456.6% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.98** (volatility 199%). Beta of 1.98 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRLD · Page: https://foliofundamentals.com/stocks/prld

Not investment advice.